{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:10:06Z","timestamp":1790244606143,"version":"4.1.0"},"reference-count":34,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Pulmonary hypertension associated with chronic lung disease remains difficult to diagnose, phenotype, and manage because vascular remodeling, parenchymal lung injury, hypoxemia, inflammation, fibrosis, and right ventricular dysfunction often coexist. Natriuretic peptides are widely used as cardiopulmonary biomarkers, but the receptor-level role of natriuretic peptide receptor-C, encoded by NPR3, remains incompletely defined. This scoping review mapped original empirical evidence on NPR-C\/NPR3 and related C-type natriuretic peptide biology in pulmonary hypertension, chronic lung disease, pulmonary vascular remodeling, and right ventricular adaptation. Methods: This scoping review was conducted and reported in accordance with PRISMA-ScR, with applicable PRISMA 2020 reporting elements addressed where relevant to a scoping review. Searches of PubMed\/MEDLINE and APA PsycINFO identified 72 records. After removal of 2 duplicates, 70 records underwent title and abstract screening. Forty-two records were excluded at this stage, and 28 reports were sought for full-text retrieval. All reports were retrieved and assessed for eligibility. Eleven reports were excluded at full-text review, leaving 17 original studies for inclusion in the evidence map. Reviews, meta-analyses, editorials, commentaries, protocols, and non-original reports were excluded from the synthesis. Results: The included studies comprised clinical biomarker studies, transcriptomic and receptor-expression analyses, experimental pulmonary hypertension models, chronic lung injury or fibrosis models, and pulmonary vascular cellular studies. Human evidence directly addressing chronic lung disease-associated pulmonary hypertension was limited and largely biomarker-centered, with CNP or NT-proCNP signals suggesting potential relevance to pulmonary vascular stress but without definitive NPR-C\/NPR3 validation. Experimental studies supported biologic plausibility, linking CNP\/NPR-C-related pathways to endothelial function, pulmonary vascular remodeling, smooth muscle and fibroblast behavior, hypoxic signaling, fibrosis, and right ventricular remodeling. However, findings varied across models, and receptor-specific attribution to NPR-C\/NPR3 was often incomplete. Conclusions: Current evidence suggests that NPR-C\/NPR3 is a biologically plausible but not yet clinically validated pathway in pulmonary hypertension associated with chronic lung disease. The strongest gap is the absence of prospective human studies integrating invasive hemodynamics, lung disease phenotyping, CNP\/NT-proCNP profiling, NPR3 expression or genetic assessment, receptor-level biology, and right ventricular outcomes. Future studies should determine whether NPR-C\/NPR3 can improve phenotyping, risk stratification, or therapeutic targeting in chronic lung disease-associated pulmonary hypertension.<\/jats:p>","DOI":"10.3390\/jcm15197429","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:07:54Z","timestamp":1790240874000},"page":"7429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natriuretic Peptide Receptor-C (NPR3) in Pulmonary Hypertension Associated with Chronic Lung Disease: A PRISMA-ScR Scoping Review of Diagnostic, Prognostic, Mechanistic, and Therapeutic Evidence"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-5477","authenticated-orcid":false,"given":"Emmanuel","family":"Eroume A Egom","sequence":"first","affiliation":[{"name":"Laboratory of Human Metabolism and Non-Communicable Diseases, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaound\u00e9 P.O. Box 13033, Cameroon"},{"name":"Institut du Savoir Montfort (ISM), Ottawa, ON K1K 0T2, Canada"},{"name":"Harmony Health Physical and Spiritual Wellness Center\/Harmony Care, Hartford, CT 06105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamou","family":"Mfopa","sequence":"additional","affiliation":[{"name":"Laboratory of Human Metabolism and Non-Communicable Diseases, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaound\u00e9 P.O. Box 13033, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njimona","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Laboratory of Human Metabolism and Non-Communicable Diseases, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaound\u00e9 P.O. Box 13033, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mountchissi","family":"C\u00e9lestin","sequence":"additional","affiliation":[{"name":"Laboratory of Human Metabolism and Non-Communicable Diseases, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaound\u00e9 P.O. Box 13033, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medou Mba","family":"Fabrice","sequence":"additional","affiliation":[{"name":"Laboratory of Human Metabolism and Non-Communicable Diseases, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaound\u00e9 P.O. Box 13033, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-7645","authenticated-orcid":false,"given":"Lum Abenwi","family":"Ambe","sequence":"additional","affiliation":[{"name":"Laboratory of Human Metabolism and Non-Communicable Diseases, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaound\u00e9 P.O. Box 13033, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Kamgang","sequence":"additional","affiliation":[{"name":"Laboratory of Human Metabolism and Non-Communicable Diseases, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaound\u00e9 P.O. Box 13033, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2018.06.001","article-title":"Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure","volume":"281","author":"Egom","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/TACG.S260755","article-title":"Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension","volume":"14","author":"Egom","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Egom, E.E.A. (2021). Natriuretic Peptide Clearance Receptor (NPR-C) Pathway as a Novel Therapeutic Target in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF). Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.674254"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1113\/jphysiol.2007.144253","article-title":"Natriuretic peptide C receptor signalling in the heart and vasculature","volume":"586","author":"Rose","year":"2008","journal-title":"J. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1172\/JCI74281","article-title":"Endothelial C-type natriuretic peptide maintains vascular homeostasis","volume":"124","author":"Moyes","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108708","DOI":"10.1016\/j.pharmthera.2024.108708","article-title":"C-type natriuretic peptide (CNP): The cardiovascular system and beyond","volume":"262","author":"Dickinson","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.lfs.2011.07.009","article-title":"C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade","volume":"89","author":"Casserly","year":"2011","journal-title":"Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21169","DOI":"10.1038\/s41598-025-08059-2","article-title":"NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD","volume":"15","author":"Avdeev","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2401200","DOI":"10.1183\/13993003.01200-2024","article-title":"Pulmonary hypertension associated with lung diseases","volume":"64","author":"Shlobin","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/thx.49.12.1247","article-title":"C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure","volume":"49","author":"Cargill","year":"1994","journal-title":"Thorax"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.rmed.2015.02.014","article-title":"Associations of circulating natriuretic peptides with haemodynamics in precapillary pulmonary hypertension","volume":"109","author":"Kaiser","year":"2015","journal-title":"Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"L328","DOI":"10.1152\/ajplung.1995.268.2.L328","article-title":"Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia","volume":"268","author":"Li","year":"1995","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"L645","DOI":"10.1152\/ajplung.1998.275.4.L645","article-title":"C-type natriuretic peptide expression and pulmonary vasodilation in hypoxia-adapted rats","volume":"275","author":"Klinger","year":"1998","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"L438","DOI":"10.1152\/ajplung.00477.2021","article-title":"Natriuretic peptide receptor-C mediates the inhibitory effect of atrial natriuretic peptide on neutrophil recruitment to the lung during acute lung injury","volume":"323","author":"Harrington","year":"2022","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e12270","DOI":"10.1002\/pul2.12270","article-title":"Deletion of the Npr3 gene increases severity of acute lung injury in obese mice","volume":"13","author":"Guarino","year":"2023","journal-title":"Pulm. Circ."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3724\/abbs.2024214","article-title":"Skeletal muscle-derived musclin attenuates glycolysis, oxidative stress, and pulmonary hypertension through the NPR3\/AKT\/mTORC1 pathway: Musclin in pulmonary hypertension","volume":"57","author":"Sun","year":"2024","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"L155","DOI":"10.1152\/ajplung.2001.281.1.L155","article-title":"Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cells","volume":"281","author":"Sun","year":"2001","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1164\/rccm.200404-455OC","article-title":"C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"170","author":"Itoh","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"L1172","DOI":"10.1152\/ajplung.00087.2004","article-title":"C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice","volume":"287","author":"Murakami","year":"2004","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s42003-024-06375-3","article-title":"C-type natriuretic peptide\/cGMP\/FoxO3 signaling attenuates hyperproliferation of pericytes from patients with pulmonary arterial hypertension","volume":"7","author":"Dabral","year":"2024","journal-title":"Commun. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s42003-025-08661-0","article-title":"C-type natriuretic peptide attenuates enhanced glycolysis and de novo pyrimidine synthesis in pericytes of patients with pulmonary arterial hypertension","volume":"8","author":"Noh","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107870","DOI":"10.1016\/j.phrs.2025.107870","article-title":"Endothelium-derived C-type natriuretic peptide offsets the pathogenesis of pulmonary hypertension","volume":"219","author":"Dignam","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1038\/s41467-026-70139-2","article-title":"Endothelial C-type natriuretic peptide\/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension","volume":"17","author":"Yanagisawa","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"He, M., Tao, K., Xiang, M., and Sun, J. (2023). Hpgd affects the progression of hypoxic pulmonary hypertension by regulating vascular remodeling. BMC Pulm. Med., 23.","DOI":"10.1186\/s12890-023-02401-y"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"eabe5407","DOI":"10.1126\/scitranslmed.abe5407","article-title":"Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension","volume":"14","author":"Chelladurai","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16044","DOI":"10.1038\/mtm.2016.44","article-title":"Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension","volume":"3","author":"Nawa","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12931-016-0335-6","article-title":"C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice","volume":"17","author":"Kimura","year":"2016","journal-title":"Respir. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133185","DOI":"10.1016\/j.ijcard.2025.133185","article-title":"Sj\u00f6gren\u2019s syndrome and pulmonary hypertension: Exploring the intricate link with interstitial lung disease","volume":"430","author":"Coppi","year":"2025","journal-title":"Int. J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.peptides.2004.09.023","article-title":"Natriuretic peptide receptor-C signaling and regulation","volume":"26","year":"2005","journal-title":"Peptides"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Moyes, A.J., and Hobbs, A.J. (2019). C-type natriuretic peptide: A multifaceted paracrine regulator in the heart and vasculature. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092281"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:38:22Z","timestamp":1790242702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":34,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197429"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197429","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}